Literature DB >> 21868047

Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol.

Yusaku Mori1, Tsutomu Hirano.   

Abstract

We attempted to elucidate the relationship between cholesterol absorption and kidney damage by investigating the renoprotective effect of ezetimibe, a cholesterol absorption inhibitor, in 5/6 nephrectomized rats (Nx). The Nx or sham-operated rats (Sham) were fed 1% high-cholesterol diet (HC) containing ezetimibe (10 mg/[kg d]), pitavastatin (3 mg/[kg d]), or both for 8 weeks. Pathological changes, endothelial nitric oxide synthase (eNOS) messenger RNA (mRNA), and oxidative stress were assessed in the kidney. The Sham fed HC exhibited hypercholesterolemia and glomerulosclerosis with macrophage infiltration in the kidney, and ezetimibe attenuated these changes. The Nx exhibited hypercholesterolemia, increased urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), glomerulosclerosis with macrophage infiltration and interstitial fibrosis, and downregulation of eNOS mRNA. The HC increased cholesterol further and worsened the kidney damage with increased 8-OHdG. Ezetimibe attenuated the hypercholesterolemia, kidney dysfunction, and pathological changes. The beneficial effects of ezetimibe were significantly associated with reduced 8-OHdG (P < .01). Pitavastatin did not reduce cholesterol or 8-OHdG, but it did significantly suppress the kidney damage with upregulated eNOS mRNA by 2.5-fold (P < .02). The combination of ezetimibe and pitavastatin synergistically ameliorated the kidney damage. The kidney dysfunction and pathological changes were significantly associated with cholesterol, markers of cholesterol absorption (campesterol and cholestanol), and 8-OHdG (P < .001-.05). Multiple regression analysis revealed that the markers of cholesterol absorption were independently associated with the kidney damage. Ezetimibe confers renoprotective effects by inhibiting cholesterol absorption, which in turn reduces oxidative stress; and pitavastatin additively ameliorates kidney damage by increasing NO production via mechanisms independent of cholesterol reduction. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21868047     DOI: 10.1016/j.metabol.2011.07.004

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Effect of Shenkang granules on the progression of chronic renal failure in 5/6 nephrectomized rats.

Authors:  Y U Zhang; Nan Zhou; Hongying Wang; Sicen Wang; Jianyu He
Journal:  Exp Ther Med       Date:  2015-03-24       Impact factor: 2.447

2.  Gender difference following high cholesterol diet induced renal injury and the protective role of rutin and ascorbic acid combination in Wistar albino rats.

Authors:  Salim Salih Al-Rejaie; Hatem Mustafa Abuohashish; Osama Abdelrahman Alkhamees; Abdulaziz Mohammed Aleisa; Abdulaziz S Alroujayee
Journal:  Lipids Health Dis       Date:  2012-03-16       Impact factor: 3.876

3.  Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice.

Authors:  Line S Bisgaard; Markus H Bosteen; Lisbeth N Fink; Charlotte M Sørensen; Alexander Rosendahl; Christina K Mogensen; Salka E Rasmussen; Bidda Rolin; Lars B Nielsen; Tanja X Pedersen
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

4.  Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.

Authors:  Genjiro Kimura; Masato Kasahara; Kenji Ueshima; Sachiko Tanaka; Shinji Yasuno; Akira Fujimoto; Toshiya Sato; Miyuki Imamoto; Shinji Kosugi; Kazuwa Nakao
Journal:  Clin Exp Nephrol       Date:  2016-07-08       Impact factor: 2.801

5.  Statins ameliorate cholesterol-induced inflammation and improve AQP2 expression by inhibiting NLRP3 activation in the kidney.

Authors:  Yonglun Kong; Weijing Feng; Xiaoduo Zhao; Puhua Zhang; Suchun Li; Zhijian Li; Yu Lin; Boen Liang; Chunling Li; Weidong Wang; Hui Huang
Journal:  Theranostics       Date:  2020-08-20       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.